Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof-of-concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients

Next Previous
Trial Profile

A proof-of-concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NVD-003 (Primary)
  • Indications Congenital disorders; Pseudoarthrosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Novadip Biosciences

Most Recent Events

  • 25 Jan 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
  • 25 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
  • 05 Jan 2024 Planned End Date changed from 1 Dec 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top